London, UK, March 29, 2019 (GLOBE NEWSWIRE) -- The asthma and COPD market benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups.
For free sample pages on this report please click on:
https://www.visiongain.com/report/pharma-leader-series-top-20-asthma-copd-companies-2019-2029/
The lead analyst of the report commented “Developments in treatment are expected to continue as new drugs and emerging technologies become more widely available. This may include personalised treatments for certain types of asthma not responding to the stepwise approach of the Global Initiative for Asthma (GINA) guidelines and treatments tailored to the specific composition of individual patient’s airway inflammation. Inhaler technology will continue to innovate with ‘intelligent’ delivery systems allowing more precise targeting of specific areas of the lungs becoming more common. In addition, inhaler-based health monitoring devices providing feedback of inhaler use to patients and healthcare professionals offer the promise of improved treatment adherence and health outcomes.”
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 207 549 9987.
Leading companies featured in the report include Aerocrine (Circassia), ALK-Abello A/S, Amphastar Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, GlaxoSmithKline, Lallemand Pharma International, Merck, MundiPharma, Novartis and more.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 207 549 9987.
For more pharma reports please visit https://www.visiongain.com/industries/pharma/
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent business intelligence providers in Europe.
Based in London, UK, Visiongain publishes independent and insightful market reports across a wide range of industry verticals, including automotive, chemical, cyber, defence, energy, pharmaceutical, materials and many more sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. The company has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original business intelligence to depend upon.
https://www.visiongain.com/